The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives
Open accessAbstract
Mammalian DNA topoisomerases II are targets of anticancer anthracyclines that act by stabilizing enzyme-DNA complexes wherein DNA strands are cut and covalently linked to the protein. This molecular mechanism is the molecular basis of anthracycline anticancer activity as well as the toxic effects such as cardiomyopathy and induction of secondary cancers. Even though anthracyclines have been used in the clinic for more than 50 years for solid and blood cancers, the search of breakthrough analogs has substantially failed. The recent developments of personalized medicine, availability of individual genomic information, and immune therapy are expected to change significantly human cancer therapy. Here, we discuss the knowledge of anthracyclines as Topoisomerase II poisons, their molecular and cellular effects and toxicity along with current efforts to improve the therapeutic index. Then, we discuss the contribution of the immune system in the anticancer activity of anthracyclines, and the need to increase our knowledge of molecular mechanisms connecting the drug targets to the immune stimulatory pathways in cancer cells. We propose that the complete definition of the molecular interaction of anthracyclines with the immune system may open up more effective and safer ways to treat patients with these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
DNA Topoisomerases: Structure, Function, and Mechanism
Champoux, J. J. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.369 · Cited by 2,743
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L.-S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. H. (2012) · Nature Medicine · doi:10.1038/nm.2919 · Cited by 1,948
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Adriamycin-Induced DNA Damage Mediated by Mammalian DNA Topoisomerase II
Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984) · Science · doi:10.1126/science.6093249 · Cited by 1,538
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
Michaud, M., Martins, I., Sukkurwala, A. Q., Adjemian, S., Ma, Y., Pellegatti, P., Shen, S., Kepp, O., Scoazec, M., Mignot, G., et al. (2011) · Science · doi:10.1126/science.1208347 · Cited by 1,377
Combination cancer immunotherapy and new immunomodulatory targets
Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · cited 1×
“Moreover, the recent combined development of personalized medicine with more accessible individual genomic data and of immune checkpoint inhibitors further promises to change significantly the therapy of human cancers [3,4].”
BackgroundCancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042 · cited 2×
“Such ‘viral mimicry’ has been even suggested to be a hallmark of clinically-effective chemotherapy [129].”
BackgroundEssential versus accessory aspects of cell death: recommendations of the NCCD 2015
Galluzzi, L., Bravo-San Pedro, J. M., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Alnemri, E. S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., et al. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.137 · Cited by 1,002
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
Pommier, Y., Sun, Y., Huang, S.-Y. N., & Nitiss, J. L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.111 · Cited by 950
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)47282-6 · Cited by 887 · cited 1×
“Initial findings clearly showed that anticancer Top2 poisons of different structural families induce DNA cleavage in a sequence-selective manner, which can be revealed experimentally as drug-specific cleavage intensity patterns in sequencing gels [47,48,57].”
BackgroundDNA topoisomerase II and its growing repertoire of biological functions
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2608 · Cited by 885
A Topoisomerase IIß-Mediated dsDNA Break Required for Regulated Transcription
Ju, B.-G., Lunyak, V. V., Perissi, V., Garcia-Bassets, I., Rose, D. W., Glass, C. K., & Rosenfeld, M. G. (2006) · Science · doi:10.1126/science.1127196 · Cited by 840
Drugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
DNA Topoisomerase I Inhibitors: Chemistry, Biology, and Interfacial Inhibition
Pommier, Y. (2009) · Chemical Reviews · doi:10.1021/cr900097c · Cited by 707
Activity-Induced DNA Breaks Govern the Expression of Neuronal Early-Response Genes
Madabhushi, R., Gao, F., Pfenning, A. R., Pan, L., Yamakawa, S., Seo, J., Rueda, R., Phan, T. X., Yamakawa, H., Pao, P.-C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.032 · Cited by 700 · cited 2×
“Moreover, the report showed reduced levels of double-strand breaks at the Fos promoter of neurons with decreased Top2β levels upon NMDA (N-methyl-D-aspartate) stimulation suggesting that Top2β is required for double-strand breakage formation for rapid gene activation [41].”
BackgroundEvolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637
Live to die another way: modes of programmed cell death and the signals emanating from dying cells
Fuchs, Y., & Steller, H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3999 · Cited by 635
Lyu, Y. L., Kerrigan, J. E., Lin, C.-P., Azarova, A. M., Tsai, Y.-C., Ban, Y., & Liu, L. F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1649 · Cited by 612
(1999) · PubMed · Cited by 546
Hensley, M. L., Hagerty, K. L., Kewalramani, T., Green, D. M., Meropol, N. J., Wasserman, T. H., Cohen, G. I., Emami, B., Gradishar, W. J., Mitchell, R. B., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2627 · Cited by 540
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
Wu, C.-C., Li, T.-K., Farh, L., Lin, L.-Y., Lin, T.-S., Yu, Y.-J., Yen, T.-J., Chiang, C.-W., & Chan, N.-L. (2011) · Science · doi:10.1126/science.1204117 · Cited by 523
STING and the innate immune response to nucleic acids in the cytosol
Burdette, D. L., & Vance, R. E. (2013) · Nature Immunology · doi:10.1038/ni.2491 · Cited by 501
Topoisomerases facilitate transcription of long genes linked to autism
King, I. F., Yandava, C. N., Mabb, A. M., Hsiao, J. S., Huang, H.-S., Pearson, B. L., Calabrese, J. M., Starmer, J., Parker, J. S., Magnuson, T., et al. (2013) · Nature · doi:10.1038/nature12504 · Cited by 438
Pang, B., Qiao, X., Janssen, L., Velds, A., Groothuis, T., Kerkhoven, R., Nieuwland, M., Ovaa, H., Rottenberg, S., van Tellingen, O., et al. (2013) · Nature Communications · doi:10.1038/ncomms2921 · Cited by 420
Secondary leukemias induced by topoisomerase-targeted drugs
Felix, C. A. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00139-0 · Cited by 418
An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes
Tamura, T., Ishihara, M., Lamphier, M. S., Tanaka, N., Oishi, I., Aizawa, S., Matsuyama, T., Mak, T. W., Taki, S., & Taniguchi, T. (1995) · Nature · doi:10.1038/376596a0 · Cited by 414
Genome Organization Drives Chromosome Fragility
Canela, A., Maman, Y., Jung, S., Wong, N., Callen, E., Day, A., Kieffer-Kwon, K.-R., Pekowska, A., Zhang, H., Rao, S. S. P., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.034 · Cited by 383
New Mechanistic and Functional Insights into DNA Topoisomerases
Chen, S. H., Chan, N.-L., & Hsieh, T.-S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061809-100002 · Cited by 369
An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes
石原, 正. (1997) · Cited by 366
DNA Topoisomerase IIβ and Neural Development
Yang, X., Li, W., Prescott, E. D., Burden, S. J., & Wang, J. C. (2000) · Science · doi:10.1126/science.287.5450.131 · Cited by 344
Transcription-dependent dynamic supercoiling is a short-range genomic force
Kouzine, F., Gupta, A., Baranello, L., Wojtowicz, D., Ben-Aissa, K., Liu, J., Przytycka, T. M., & Levens, D. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2517 · Cited by 334
Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy
Bailly, C. (2012) · Chemical Reviews · doi:10.1021/cr200325f · Cited by 288
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
Azarova, A. M., Lyu, Y. L., Lin, C.-P., Tsai, Y.-C., Lau, J. Y.-N., Wang, J. C., & Liu, L. F. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704002104 · Cited by 286
Drake, F., Zimmerman, J., McCabe, F., Bartus, H., Per, Sr., Sullivan, D., Ross, W., Mattern, M., Johnson, R., & Crooke, S. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)49317-9 · Cited by 277
Classen, S., Olland, S., & Berger, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1832879100 · Cited by 263
Capranico, G., Tinelli, S., Austin, C. A., Fisher, M. L., & Zunino, F. (1992) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(92)90050-a · Cited by 258
Self-citationGuryanova, O. A., Shank, K., Spitzer, B., Luciani, L., Koche, R. P., Garrett-Bakelman, F. E., Ganzel, C., Durham, B. H., Mohanty, A., Hoermann, G., et al. (2016) · Nature Medicine · doi:10.1038/nm.4210 · Cited by 256
Topoisomerase II beta interacts with cohesin and CTCF at topological domain borders
Uusküla-Reimand, L., Hou, H., Samavarchi-Tehrani, P., Rudan, M. V., Liang, M., Medina-Rivera, A., Mohammed, H., Schmidt, D., Schwalie, P., Young, E. J., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1043-8 · Cited by 255
Dynamics of human DNA topoisomerases IIα and IIβ in living cells
Christensen, M. O., Larsen, M. K., Barthelmes, H. U., Hock, R., Andersen, C. L., Kjeldsen, E., Knudsen, B. R., Westergaard, O., Boege, F., & Mielke, C. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200112023 · Cited by 199
Hughes, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2813 · Cited by 191
Capranico, G., Kohn, K. W., & Pommier, Y. (1990) · Nucleic Acids Research · doi:10.1093/nar/18.22.6611 · Cited by 186
Self-citationRole of Topoisomerase IIβ in the Expression of Developmentally Regulated Genes
Lyu, Y. L., Lin, C.-P., Azarova, A. M., Cai, L., Wang, J. C., & Liu, L. F. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00617-06 · Cited by 179
Mitotic chromosomes are compacted laterally by KIF4 and condensin and axially by topoisomerase IIα
Samejima, K., Samejima, I., Vagnarelli, P., Ogawa, H., Vargiu, G., Kelly, D. A., de Lima Alves, F., Kerr, A., Green, L. C., Hudson, D. F., et al. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201202155 · Cited by 178
DNA topoisomerase I and II in cancer chemotherapy: update and perspectives
Pommier, Y. (1993) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00685611 · Cited by 174
Cowell, I. G., Sondka, Z., Smith, K., Lee, K. C., Manville, C. M., Sidorczuk-Lesthuruge, M., Rance, H. A., Padget, K., Jackson, G. H., Adachi, N., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204406109 · Cited by 168
Anthracycline-Induced Cardiotoxicity
Ferreira, A., Matsubara, L., & Matsubara, B. (2008) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152508785909474 · Cited by 168
Strissel, P. L., Strick, R., Rowley, J. D., & Zeleznik‐Le, N. J. (1998) · Blood · doi:10.1182/blood.v92.10.3793 · Cited by 165
Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery
Pommier, Y., & Cherfils, J. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.008 · Cited by 165
Tiwari, V. K., Burger, L., Nikoletopoulou, V., Deogracias, R., Thakurela, S., Wirbelauer, C., Kaut, J., Terranova, R., Hoerner, L., Mielke, C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119798109 · Cited by 165
PhytoNanotechnology: Enhancing Delivery of Plant Based Anti-cancer Drugs
Khan, T., & Gurav, P. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.01002 · Cited by 165
Turley, H., Comley, M., Houlbrook, S., Nozaki, N., Kikuchi, A., Hickson, I., Gatter, K., & Harris, A. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.227 · Cited by 162
Turcotte, L. M., Neglia, J. P., Reulen, R. C., Ronckers, C. M., van Leeuwen, F. E., Morton, L. M., Hodgson, D. C., Yasui, Y., Oeffinger, K. C., & Henderson, T. O. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.7764 · Cited by 160
Capranico, G., Zunino, F., Kohn, K. W., & Pommier, Y. G. (1990) · Biochemistry · doi:10.1021/bi00454a033 · Cited by 156
Self-citationCapranico, G., Marinello, J., & Chillemi, G. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00966 · Cited by 150
Self-citationGebremeskel, S., & Johnston, B. (2015) · Oncotarget · doi:10.18632/oncotarget.6113 · Cited by 149
Feng, W., Kawauchi, D., Körkel-Qu, H., Deng, H., Serger, E., Sieber, L., Lieberman, J. A., Jimeno-González, S., Lambo, S., Hanna, B. S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14758 · Cited by 142
Austin, C. A., Sng, J.-H., Patel, S., & Fisher, L. M. (1993) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(93)90215-y · Cited by 139
Carpenter, A. J., & Porter, A. C. G. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-08-0732 · Cited by 139
Interleukin-13 receptor–targeted nanovesicles are a potential therapy for glioblastoma multiforme
Madhankumar, A. B., Slagle‐Webb, B., Mintz, A., Sheehan, J. M., & Connor, J. R. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0480 · Cited by 130
Madhankumar, A. B., Slagle‐Webb, B., Wang, X., Yang, Q. X., Antonetti, D. A., Miller, P. A., Sheehan, J. M., & Connor, J. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0853 · Cited by 124
Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIβ
Lyu, Y. L., & Wang, J. C. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1232376100 · Cited by 121
Activation of Interferon Regulatory Factor 3 in Response to DNA-damaging Agents
Kim, T. I., Kim, T. Y., Song, Y., Min, I. M., Yim, J., & Kim, T. K. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30686 · Cited by 116
Lapatinib and doxorubicin enhance the S tat1‐dependent antitumor immune response
Hannesdóttir, L., Tymoszuk, P., Parajuli, N., Wasmer, M.-H., Philipp, S., Daschil, N., Datta, S., Koller, J., Tripp, C. H., Stoitzner, P., et al. (2013) · European Journal of Immunology · doi:10.1002/eji.201242505 · Cited by 115
Review: Cell Death, Nucleic Acids, and Immunity
Elkon, K. B. (2018) · Arthritis & Rheumatology · doi:10.1002/art.40452 · Cited by 108
Luthra, P., Aguirre, S., Yen, B. C., Pietzsch, C. A., Sánchez-Aparicio, M. T., Tigabu, B., Morlock, L., García‐Sastre, A., Leung, D. W., Williams, N. S., et al. (2017) · mBio · doi:10.1128/mbio.00368-17 · Cited by 106
NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform
Toyoda, E., Kagaya, S., Cowell, I. G., Kurosawa, A., Kamoshita, K., Nishikawa, K., Iiizumi, S., Koyama, H., Austin, C. A., & Adachi, N. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803936200 · Cited by 102
Austin, C. A., Lee, K. C., Swan, R. L., Khazeem, M. M., Manville, C. M., Cridland, P., Treumann, A., Porter, A., Morris, N. J., & Cowell, I. G. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092765 · Cited by 102
Chiral ruthenium(II) anthraquinone complexes as dual inhibitors of topoisomerases I and II
Kou, J., Qian, C., Wang, J., Chen, X., Wang, L., Chao, H., & Ji, L. (2011) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-011-0831-6 · Cited by 100
Binaschi, M., Capranico, G., Bo, L. D., & Zunino, F. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.6.1053 · Cited by 94
Self-citationZhang, H., Zhang, Y., Yasukawa, T., Rosa, I. D., Khiati, S., & Pommier, Y. G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku384 · Cited by 93
Gene regulation and priming by topoisomerase IIα in embryonic stem cells
Thakurela, S., Garding, A., Jung, J., Schübeler, D., Burger, L., & Tiwari, V. K. (2013) · Nature Communications · doi:10.1038/ncomms3478 · Cited by 91
A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons
Capranico, G., Binaschi, M., Borgnetto, M. E., Zunino, F., & Palumbo, M. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01095-x · Cited by 82
Self-citationA Journey in the World of DNA Rings and Beyond
Wang, J. C. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.030107.090101 · Cited by 76
Ray, S., Panova, T. B., Miller, G., Volkov, A., Porter, A. C. G., Russell, J., Panov, K. I., & Zomerdijk, J. C. B. M. (2013) · Nature Communications · doi:10.1038/ncomms2599 · Cited by 74
Differential expression of the topoisomerase IIα and β genes in human breast cancers
Sandri, M., Hochhauser, D., Ayton, P. M., Camplejohn, R., Whitehouse, R. M., Turley, H., Gatter, K. C., Hickson, I. D., & Harris, A. L. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.286 · Cited by 72
Cornarotti, M., Tinelli, S., Willmore, E., Zunino, F., Fisher, L. M., Austin, C. A., & Capranico, G. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09603-8 · Cited by 72
Self-citationTopoisomerases and the regulation of neural function
McKinnon, P. J. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.101 · Cited by 71
Hasinoff, B. B., Wu, X., Patel, D., Kanagasabai, R., Karmahapatra, S. K., & Yalowich, J. C. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.228650 · Cited by 64
Shchekotikhin, A. E., Dezhenkova, L. G., Цветков, В. Б., Luzikov, Y. N., Volodina, Y. L., Tatarskiy, V. V., Kalinina, A. A., Treschalin, M. I., Treshalina, H. M., Романенко, В. И., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.050 · Cited by 60
Sano, K., Miyaji‐Yamaguchi, M., Tsutsui, K., & Tsutsui, K. (2008) · PLoS ONE · doi:10.1371/journal.pone.0004103 · Cited by 59
Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells
Manville, C. M., Smith, K. A., Sońdka, Z., Rance, H. A., Cockell, S., Cowell, I. G., Lee, K. C., Morris, N. J., Padget, K., Jackson, G. H., et al. (2015) · Biology Open · doi:10.1242/bio.014308 · Cited by 57
Hisatomi, T., Sueoka‐Aragane, N., Sato, A., Tomimasu, R., Ide, M., Kurimasa, A., Okamoto, K., Kimura, S. H., & Sueoka, E. (2011) · Blood · doi:10.1182/blood-2010-02-270439 · Cited by 53
Pommier, Y. G., Kiselev, E., & Marchand, C. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.032 · Cited by 53
Ke, X., Lin, W., Li, X., Wang, H., Xiao, X., & Guo, Z. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1396384 · Cited by 46
A protein-mediated mechanism for the DNA sequence-specific action of topoisomerase II poisons
Capranico, G., Binaschi, M., Borgnetto, M. E., Zunino, F., & Palumbo, M. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)90658-1 · Cited by 46
Self-citationDoxorubicin and rhein loaded nanomicelles attenuates multidrug resistance in human ovarian cancer
Han, N., Li, X., Tao, L., & Zhou, Q. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.01.042 · Cited by 41
Shi, J., Su, Y.-C., Liu, W., Chang, J., & Zhang, Z. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s143776 · Cited by 39
Binaschi, M., Farinosi, R., Borgnetto, M. E., & Capranico, G. (2000) · PubMed · Cited by 37
Self-citationSantiago, T., DeVaux, R., Kurzątkowska, K., Espinal, R., Herschkowitz, J. I., & Hepel, M. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s149306 · Cited by 34
Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules
Mariani, A., Bartoli, A., Atwal, M., Lee, K. C., Austin, C. A., & Rodriguez, R. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00473 · Cited by 23
Khobta, A., Carlo‐Stella, C., & Capranico, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1126 · Cited by 20
Self-citationAsakura, T., Yokoyama, M., SHIRAISHI, K., Aoki, K., & Ohkawa, K. (2018) · Anticancer Research · doi:10.21873/anticanres.12353 · Cited by 9
Cited by
Ligands stimulating antitumour immunity as the next G-quadruplex challenge
Miglietta, G., Marinello, J., Russo, M., & Capranico, G. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01649-y · Cited by 44
“and topoisomerase‐mediated genome instability Immuno-modulation activity has been proposed also for Topoisomerase poisons arguing that immune-stimulation can contribute significantly to the therapeutic activity of established anticancer agents in patients [114, 115].”
BackgroundSelf-citationInsights into P-Glycoprotein Inhibitors: New Inducers of Immunogenic Cell Death
Kopecka, J., Godel, M., Dei, S., Giampietro, R., Belisario, D. C., Akman, M., Contino, M., Teodori, E., & Riganti, C. (2020) · Cells · doi:10.3390/cells9041033 · Cited by 41
Metadata
- Authors
- Marinello, J., Delcuratolo, M., & Capranico, G.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-06
- Volume
- 19
- Issue
- 11
- Pages
- 3480
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2899552791
- Cited by
- 258
- References
- 96
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.